The following information is based on the news shared in the Bradenton Times.
Gilead has partnered with Ronald J. Cirillo, MD, medical director of Turning Points, Bradenton’s one-stop center for the medically needy at 701 17th Ave. W., Bradenton.
We all know that Harvoni a combination of Sofosbuvir 400mg and Ledipasvir 90mg has been a total success for the treatment of Hep C genotype 1 and genotype 4.
Gilead will take part in Hep C research and the project will be handled by Dr. Cirillo the medical director of Turning Points.
Since the price of the medication is massive it will be interesting to note the number of Hep C patients that will be covered in this research.
The research will be conducted for an unspecified amount of time by students from Lake Erie College of Osteopathic Medicine.
The findings will be out in a scientific journal.
Gilead is definitely taking a big plunge here, but data also supports 99% success rate of its Indian licensed generics. Sofosbuvir 400mg + Ledipasvir 90mg, Sofosbuvir 400mg, and Sofosbuvir 400mg + Velpatasvir 100mg.
Successful treatment requires 12 weeks and in some cases 24 weeks, but this definitely makes the future positive for patients suffering from chronic Hep C.
For more information on the program call 941-567-6156 or for the generic program visit
here.Read more here: http://www.bradenton.com/news/local/article132520179.html?utm_medium=social&utm_campaign=postplanner&utm_source=facebook.com#storylink=cpy